Target intelligence / Profile preview

Non-muscle myosin heavy chain IIA (MYH9)

Target
MYH9
Molecular classification
Enzyme, Receptor, Other
01

Overview

Non-muscle myosin heavy chain IIA (NMHC IIA), encoded by the MYH9 gene, is a key subunit of non-muscle myosin IIA (NM IIA), an actin-based molecular motor that utilizes ATP hydrolysis to generate mechanical force. It plays a fundamental role in essential cellular processes, including cytokinesis, cell migration, polarization, adhesion, maintenance of cell shape, and intracellular transport. NMHC IIA is widely expressed in various tissues and is particularly critical for platelet formation and function, as well as renal podocyte integrity. Mutations in the MYH9 gene lead to a group of autosomal dominant disorders collectively known as MYH9-related diseases (MYH9-RD), characterized by macrothrombocytopenia, sensorineural hearing loss, cataracts, and progressive glomerulonephritis.

In oncology, MYH9 is frequently overexpressed in multiple cancers (such as breast, lung, gastric, and esophageal cancers) and is associated with tumor invasion, metastasis, epithelial-to-mesenchymal transition (EMT), and resistance to chemotherapies. It also acts as a host cell receptor or entry mediator for several viruses, including herpes simplex virus 1 (HSV-1). Pharmacological targeting of MYH9 primarily involves small-molecule inhibitors like blebbistatin, which directly block its ATPase activity and disrupt actomyosin contractility. Other therapeutic strategies focus on modulating MYH9 expression or its upstream regulatory pathways (such as ROCK or PI3K/AKT/mTOR) to suppress cancer progression and metastasis.

Other names
Myosin-9Myosin heavy chain 9Non-muscle myosin heavy chain ANon-muscle myosin heavy chain IIaCellular myosin heavy chain type ANMMHC-ANMMHC-IIANMHC IIA
02

Mechanism of action

Direct inhibition of the ATPase activity of the myosin motor domain, preventing actin-myosin interaction and actomyosin contractility; indirect modulation of expression or phosphorylation levels to affect downstream signaling pathways such as PI3K/AKT/mTOR and beta-catenin.

03

Biological functions

Signal transductionCell cycleCell proliferationOther
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

ThrombocytopeniaBleeding riskSensorineural hearing lossRenal dysfunction or failureCataractsImpaired wound healingImpaired cell motility
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

MYH9 expression levelMYH9 mutation statusMYH9 phosphorylation statusNeutrophil inclusions of myosin-9Macrothrombocytopenia

Beyond the preview

Go deeper on Non-muscle myosin heavy chain IIA (MYH9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-muscle myosin heavy chain IIA (MYH9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call